VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
PHGKoninklijke Philips N.V.
$27.10$25.8B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksPHGFinancials

Koninklijke Philips N.V. (PHG) Financials

30Y historyFree accessUpdated daily

Revenue growth remains negative at -3.1% in 2026Q1, while operating margins continue to fluctuate, peaking at only 10.6% in 2025Q4.

PHG Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Sales/Revenue17.71B17.83B18.02B18.17B17.83B17.16B17.31B17.15B18.12B17.78B24.52B24.24B21.39B23.33B24.79B22.58B25.42B23.19B26.39B26.84B26.98B30.37B30.3B28.99B31.85B32.4B37.97B31.55B30.29B34.31B31.92B
Revenue Growth %-1.52%-1.04%-0.81%1.92%3.91%-0.91%0.97%-5.38%1.92%-27.48%1.12%13.34%-8.31%-5.89%9.78%-11.17%9.62%-12.11%-1.68%-0.52%-11.18%0.25%4.52%-8.99%-1.69%-14.67%20.33%4.17%-11.71%7.48%2.02%
Cost of Goods Sold9.7B9.78B10.25B10.72B10.63B9.99B9.4B9.2B9.57B9.6B13.9B14.39B13.19B13.64B15.38B13.93B15.87B15.11B17.92B17.65B18.68B20.56B20.14B19.52B21.93B22.85B28.77B24.57B23.99B25.83B24.61B
COGS % of Revenue-54.82%56.87%59.01%59.65%58.22%54.3%53.65%52.8%53.99%56.71%59.35%61.64%58.47%62.04%61.7%62.45%65.16%67.91%65.78%69.25%67.7%66.48%67.36%68.84%70.55%75.78%77.89%79.19%75.29%77.12%
Gross Profit8B8.06B7.77B7.45B7.19B7.17B7.91B7.95B8.55B8.18B10.61B9.86B8.21B9.69B9.41B8.65B9.55B8.08B8.47B9.18B8.3B9.81B10.16B9.46B9.92B9.54B9.2B6.98B6.3B8.48B7.3B
Gross Margin %45.2%45.18%43.13%40.99%40.35%41.78%45.7%46.35%47.2%46.01%43.29%40.65%38.36%41.53%37.96%38.3%37.55%34.84%32.09%34.22%30.75%32.3%33.52%32.64%31.16%29.45%24.22%22.11%20.81%24.71%22.88%
Gross Profit Growth %-3.67%4.36%3.53%0.36%-9.4%-0.45%-7.07%4.56%-22.92%7.67%20.11%-15.3%2.97%8.81%-9.42%18.16%-4.58%-7.8%10.71%-15.44%-3.41%7.33%-4.64%4%3.77%31.78%10.72%-25.67%16.08%-22.87%
Operating Expenses6.52B6.63B7.24B7.56B8.72B6.62B6.65B6.58B6.83B6.65B8.73B8.86B7.72B7.67B8.38B7.56B7.48B7.46B8.11B7.33B7.11B8.03B8.26B8.57B9.01B9.45B4.74B5.18B5.29B6.21B6.13B
OpEx % of Revenue-37.2%40.2%41.63%48.93%38.56%38.4%38.39%37.72%37.42%35.6%36.56%36.08%32.87%33.8%33.49%29.43%32.19%30.74%27.31%26.37%26.43%27.27%29.56%28.28%29.17%12.5%16.41%17.48%18.09%19.22%
Selling, General & Admin4.9B4.97B5.07B5.13B5.29B4.86B4.55B4.56B5.13B4.97B6.73B7.02B5.87B6.02B6.27B6B5.98B5.89B6.51B5.84B5.68B5.93B5.85B6.06B6.43B6.27B6.28B5.57B5.48B6.34B6.29B
SG&A % of Revenue-27.87%28.12%28.25%29.69%28.31%26.29%26.59%28.32%27.98%27.46%28.97%27.45%25.82%25.28%26.58%23.53%25.41%24.67%21.77%21.05%19.52%19.3%20.89%20.18%19.35%16.53%17.64%18.1%18.47%19.69%
Research & Development1.64B1.7B1.75B1.89B2.09B1.81B1.91B1.79B1.76B1.76B2.02B1.93B1.64B1.73B1.81B1.61B1.58B1.63B1.78B1.63B1.67B2.55B2.53B2.61B3.05B3.32B00000
R&D % of Revenue-9.53%9.69%10.4%11.73%10.53%11.06%10.44%9.71%9.92%8.24%7.95%7.64%7.43%7.3%7.13%6.2%7.03%6.73%6.08%6.18%8.4%8.36%9.01%9.56%10.24%-----
Other Operating Expenses-1000K-36M429M541M1.34B-48M183M232M9M21M00211M-32M326M-50M00000000-466M-137.12M-1.53B-388.57M-189.29M-130M-151.86M
Operating Income1.48B1.42B529M-115M-1.53B553M1.26B1.37B1.72B1.52B1.88B992M486M1.99B1.03B-269M2.06B614M54M1.85B1.18B1.78B1.61B487.53M420.26M-1.37B4.29B1.76B681.28M2.23B835.61M
Operating Margin %8.37%7.98%2.94%-0.63%-8.58%3.22%7.3%7.97%9.49%8.53%7.68%4.09%2.27%8.53%4.16%-1.19%8.12%2.65%0.2%6.91%4.38%5.85%5.3%1.68%1.32%-4.24%11.31%5.57%2.25%6.49%2.62%
Operating Income Growth %-169.19%560%92.48%-376.49%-56.25%-7.47%-20.54%13.32%-19.39%89.72%104.12%-75.59%93.3%482.9%-113.03%236.32%1037.04%-97.09%56.8%-33.45%10.67%229.4%16.01%130.6%-131.99%144.47%157.76%-69.39%166.33%-51.21%
EBITDA2.6B2.55B1.92B1.15B73M1.88B2.33B2.27B2.81B2.54B3.15B2.27B1.67B3.34B2.46B1.19B3.49B2.08B1.24B2.71B2.02B3.28B3.9B2.5B2.61B1.43B6.62B3.61B2.56B3.9B2.5B
EBITDA Margin %14.68%14.29%10.64%6.31%0.41%10.93%13.46%13.24%15.5%14.3%12.84%9.38%7.82%14.32%9.94%5.26%13.72%8.98%4.71%10.09%7.48%10.81%12.86%8.62%8.18%4.41%17.44%11.46%8.45%11.38%7.82%
EBITDA Growth %5.58%32.9%67.36%1469.86%-96.11%-19.52%2.69%-19.16%10.46%-19.28%38.54%35.86%-49.91%35.61%107.5%-65.96%67.4%67.44%-54.05%34.22%-38.59%-15.72%55.96%-4.13%82.46%-78.42%83.14%41.16%-34.42%56.46%-20.37%
D&A (Non-Cash Add-back)1.12B1.13B1.39B1.26B1.6B1.32B1.07B904M1.09B1.02B1.27B1.28B1.19B1.35B1.43B1.46B1.42B1.47B1.19B852.54M834.22M1.51B2.29B2.01B2.19B2.8B2.33B1.86B1.88B1.68B1.66B
EBIT1.54B1.51B460M-220M-1.49B673M1.69B1.72B1.71B1.62B1.38B782M600M1.93B698M-366M2.29B839M1.65B1.86B1.2B1.56B1.16B894.08M916.76M93.28M4.45B1.8B1.02B1.74B688.57M
Net Interest Income-233.12M-223.8M-257M-260M-219M-146M-178.98M-179.08M-219M-81M-421M-223M-188M-330M-329M-331M-121M-166M88M000000000000
Interest Income117.22M108.54M79M46M25M18M14.82M30.22M51M126M76M98M114M70M106M112M214M225M140M000000000000
Interest Expense350.17M332.34M337M306M244M164M193.8M209.3M264M263M569M467M415M400M352M352M336M391M246M0000439.1M5.97B4.6B00001.58B
Other Income/Expense-211.31M-242M-406M-412M-202M-44M-53M-119M-216M-140M-75M-329M-239M-194M-329M-541M-131M-166M88M2.62B28.03M1.28B666.13M204.86M-3.6B-1.66B5.91B390.56M-103.17M213.64M-714.28M
Pretax Income1.27B1.18B123M-527M-1.73B509M1.21B1.25B1.5B1.38B1.39B623M185M1.66B784M-509M1.94B448M142M4.47B1.22B1.89B1.82B692.39M-3.18B-3.03B10.2B2.15B578.96M1.91B439.5M
Pretax Margin %7.18%6.63%0.68%-2.9%-9.71%2.97%6.99%7.27%8.29%7.74%5.67%2.57%0.86%7.12%3.16%-2.25%7.64%1.93%0.54%16.66%4.51%6.21%6.01%2.39%-9.99%-9.35%26.87%6.8%1.91%5.56%1.38%
Income Tax299.72M282M963M-73M-113M-103M212M258M193M349M327M239M26M466M308M283M509M100M256M622.77M137.14M585.95M357.77M-15.09M26.68M-421.47M571.77M336.89M40.93M431.82M106.06M
Effective Tax Rate %23.58%23.86%782.93%13.85%6.53%-20.24%17.51%20.69%12.84%25.34%23.54%38.36%14.05%28.06%39.29%-55.6%26.2%22.32%180.28%13.93%11.27%31.08%19.64%-2.18%-0.84%13.91%5.61%15.69%7.07%22.63%24.13%
Net Income972.48M895M-702M-466M-1.61B3.32B1.19B1.17B1.09B1.66B1.45B645M415M1.17B226M-1.29B1.45B410M-92M4.17B5.38B2.87B2.83B693.19M-3.21B-2.61B9.63B1.8B6.02B2.57B-272.38M
Net Margin %5.49%5.02%-3.9%-2.56%-9.02%19.35%6.86%6.81%6.02%9.32%5.91%2.66%1.94%5.01%0.91%-5.74%5.69%1.77%-0.35%15.56%19.96%9.44%9.35%2.39%-10.07%-8.05%25.36%5.72%19.88%7.5%-0.85%
Net Income Growth %160.72%227.49%-50.64%71.02%-148.45%179.61%1.71%7.06%-34.22%14.43%124.5%55.42%-64.5%417.26%117.45%-189.56%252.68%545.65%-102.2%-22.45%87.81%1.14%308.86%121.6%-23%-127.09%433.51%-70.02%134.07%1044.21%-121.12%
Net Income (Continuing)971.4M900M-840M-454M-1.62B612M999M989M1.31B1.03B831M160M221M1.03B-166M-1.05B1.47B424M-95M4.61B900.89M2.88B2.58B707.48M-3.21B-2.61B9.63B1.81B541.44M1.22B128.56M
Discontinued Operations-1000K-4M142M-10M13M2.71B196M183M0843M660M479M190M138M00000000000000000
Minority Interest26.03M32M37M33M34M36M31M28M29M24M907M118M101M13M34M34M46M49M46M41.84M131.08M331.81M282.53M174.69M179.16M202.3M470.62M333.91M240.45M1.08B699.02M
EPS (Diluted)1.000.93-0.75-0.49-1.680.641.231.201.091.641.460.660.421.190.23-1.271.440.41-0.093.584.272.152.070.51-2.36-1.916.791.324.261.88-0.19
EPS Growth %152.5%224%-53.06%70.83%-362.5%-47.97%2.5%10.09%-33.54%12.33%121.21%57.14%-64.71%417.39%118.11%-188.19%251.22%573.44%-102.42%-16.16%98.6%3.86%305.88%121.61%-23.56%-128.13%414.39%-69.01%126.6%1089.47%-182.61%
EPS (Basic)-0.95-0.75-0.49-1.680.671.251.211.111.671.480.660.421.200.23-1.281.440.41-0.093.614.302.152.080.51-2.36-1.916.861.324.291.88-0.19
Diluted Shares Outstanding968.53M962.5M933.37M948.79M952.46M950.28M957.56M972.79M997.48M1.01B989.95M984.45M983.48M982.79M987.99M1.02B1.01B990.22M1.06B1.17B1.26B1.34B1.37B1.36B1.36B1.36B1.42B1.37B1.37B1.37B1.4B
Basic Shares Outstanding951.57M962.37M933.37M948.79M952.46M907.46M948.26M962.2M983.77M989.96M978.47M976.41M975.46M971.07M987.99M1.02B1B986.43M1.06B1.16B1.25B1.33B1.36B1.36B1.36B1.36B1.4B1.37B1.37B1.37B1.4B
Dividend Payout Ratio-36.65%---17.17%0.08%43.45%36.79%23.17%22.79%46.2%70.36%23.27%112.83%-20.47%154.63%--9.71%17.56%16.22%66.21%--4.16%20.04%5.4%9.72%-

Key Metrics

Growth RegimeContracting
ProfitabilityStrained
Balance SheetStrained
Cash FlowMixed
Top Statement Risk

Regulatory and litigation overhang

Persistent Revenue Contraction Trends

As indicated by the most recent quarterly data, Philips continues to struggle with top-line growth, reporting a 3.1% revenue decline in 2026Q1, which underscores the ongoing difficulty in reversing a multi-quarter trend of negative year-over-year performance across its core medical technology and consumer segments.

The consistent inability to achieve positive revenue growth suggests that the company is losing market share or facing significant headwinds in its hospital equipment installation cycles. Investors should monitor whether the shift toward informatics and software-led revenue can eventually offset the structural decline in legacy hardware sales.

Structural Margin Volatility Remains Elevated

According to the provided financial statements, gross margins have fluctuated significantly, dropping to 38.9% in 2024Q4 before recovering to 45.2% in 2026Q1, reflecting the company's ongoing struggle to maintain pricing power amidst supply chain disruptions and the high costs of remediating its product portfolio.

The volatility in gross margins suggests that Philips lacks the consistent pricing power seen in its more specialized med-tech peers. This instability appears to be a direct consequence of operational inefficiencies and the high cost of maintaining quality control in its complex manufacturing environment.

Operating Leverage Constrained by Overhead

Based on reported figures, operating margins have remained thin, peaking at 10.6% in 2025Q4 but frequently dipping into low single digits, which indicates that the company has failed to achieve meaningful operating leverage despite its significant scale and long-standing presence in the global healthcare market.

The persistent gap between gross profit and operating income suggests that SG&A expenses remain disproportionately high, likely due to ongoing restructuring and legal costs. This lack of scalability implies that the current operating model may be too bloated to deliver the margin expansion expected by shareholders.

Earnings Distorted by Non-Operating Items

As evidenced by the extreme variance in net income, ranging from a $999 million loss in 2024Q1 to a $451 million profit in 2024Q2, the quality of reported earnings appears highly compromised by non-recurring litigation charges and significant restructuring expenses that obscure underlying operational performance.

The erratic nature of EPS suggests that investors should rely more on normalized cash flow metrics rather than reported net income to gauge the company's true health. The frequent inclusion of large, non-operating charges warrants deep skepticism regarding the sustainability of current bottom-line profitability.

Structural Risks to Turnaround Narrative

While management emphasizes a pivot toward high-margin software, the income statement data reveals that R&D spending remains elevated at over $400 million per quarter without yielding a clear inflection in revenue growth, suggesting that the company's technological investments may not be translating into competitive market advantages.

Short-sellers would likely focus on the fact that the company continues to burn through significant capital while struggling to stabilize its core business. The reliance on recurring service revenue may not be sufficient to offset the potential for further market share loss in the competitive respiratory and imaging sectors.

PHG — Frequently Asked Questions

Quick answers to the most common questions about buying PHG stock.

What was Koninklijke Philips N.V.'s (PHG) revenue in 2025?

For fiscal year 2025, Koninklijke Philips N.V. (PHG) reported total revenue of $17.83B. This represents a 44.1% decline compared to $31.92B in 1996.

Is Koninklijke Philips N.V. (PHG) profitable?

Koninklijke Philips N.V. (PHG) is profitable, generating $895.0M in net income for the fiscal year ending 2025 with a net profit margin of 5.0%.

What is Koninklijke Philips N.V.'s operating profit margin?

Koninklijke Philips N.V. (PHG) reported an operating income of $1.42B, resulting in an operating profit margin of 8.0%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Koninklijke Philips N.V.'s gross profit and gross margin?

Koninklijke Philips N.V. (PHG) generated $8.06B in gross profit for the year, representing a gross profit margin of 45.2%. This demonstrates the company's core pricing power and production efficiency.